Refine
Document Type
- Article (14)
- Doctoral Thesis (2)
- Master's Thesis (1)
Has Fulltext
- yes (17)
Is part of the Bibliography
- no (17)
Keywords
- stroke (17) (remove)
Institute
- Medizin (16)
- Informatik (1)
In dieser Studie wurden Patienten untersucht, die einen malignen Hirninfarkt erlitten hatten und mit Hilfe der dekompressiven Hemikraniektomie behandelt wurden. Es wurden die funktionelle Beeinträchtigung, die Körperbehinderung und die Lebensqualität untersucht. Die Patienten wurden sechs Monate nach dem Ereignis kontaktiert, um eine Nachuntersuchung durchzuführen. Dabei wurden die Patienten bezüglich ihrer Beeinträchtigung, Körperbehinderung und Lebensqualität beurteilt. Die Studie beinhaltete 36 Patienten. Daraus resultiert eine Überlebensrate von 64%. Bei 10 Patienten wurde die Beeinträchtigung mit dem Barthel Index mit 50 Punkten beurteilt. In drei Fällen betrug der BI 90 Punkte. Die Mehrheit der Patienten (12) zeigte ernste Beeinträchtigungen (BI<50). Die Behinderung korrelierte negativ mit dem Patientenalter. 16 Patienten waren nicht in der Lage zu gehen und benötigten bei der täglichen Arbeit Hilfe, was einen mRS von 4 oder 5 Punkten entspricht. Keiner der Patienten erreichte einen unabhängigen Status. Patienten, die eine höhere BI-Punktezahl hatten, waren signifikant jünger, hatten weniger schwere Beeinträchtigungen bei der Krankenhausaufnahme, wurden kürzer mechanisch ventiliert und verließen die Intensivstation früher. Die Schwere der Angst oder der Depression korrelierte dabei signifikant mit der Schwere der Behinderung. Die dekompressive Hemikraniektomie verbessert die Überlebensrate dramatisch, reduziert aber nicht die Größe des Infarktvolumens. Die Mehrzahl der Patienten wurde durch den Infarkt deutlich in ihrem Leben beeinträchtigt. Insgesamt ist die Lebensqualität reduziert.
Atherosklerotische Stenosen der Karotiden sind eine häufige Erkrankung mit variablem Verlauf und stellen durch ihre potentielle Emboligenität einen wichtigen Risikofaktor für zerebrale Ischämien dar. Klinische und paraklinische Parameter helfen, das individuelle Schlaganfallrisiko bei Patienten mit hochgradigen ACI-Stenosen einzuschätzen, das unmittelbar nach einem thrombembolischen Ereignis besonders hoch ist. Als histomorphologisches Korrelat dieser "Vulnerabilität" wird die Ruptur der fibrotischen Deckplatte der Plaque propagiert, die häufiger bei symptomatischen Patienten nachzuweisen ist. Sie korreliert mit der Infiltration der Gefäßwand durch aktivierte Leukozyten, die über molekulare und zelluläre Interaktionen die Zell- und Bindegewebskomposition der Plaque verändern können. Die strukturelle Integrität atherosklerotischer Läsionen beruht auf der extrazellulären Vernetzung von kollagenem Bindegewebe, das überwiegend von phänotypisch veränderten glatten Gefäßmuskelzellen produziert wird. Eine Hypothese besagt, dass die im Rahmen der Inflammation stattfindende Zunahme proapoptotischer Mediatoren über eine Ausdünnung der zellulären und bindegewebigen Strukturen zu einem Verlust an mechanischer Stabilität führt und somit eine symptomatische Ruptur begünstigt. Da der Nachweis einer Ruptur mit Exponierung des thrombogenen nekrotischen Kerns allerdings nur in einem Teil der symptomatischen Plaques und umgekehrt auch in einem Teil der asymptomatischen nachgewiesen werden kann, ist aber bislang unklar, ob o.g. Abläufe in der humanen Karotis-Atherosklerose tatsächlich mit einer klinischen Relevanz einhergehen. In der vorliegenden Arbeit wurde daher das Auftreten der Apoptose von glatten Gefäßmuskelzellen (mittels DNA in situ end labeling Technik, TUNEL-Färbung) in 38 prospektiv gesammelten Endarterektomie-Präparaten hochgradiger Karotisstenosen quantitativ erfasst und statistisch in Beziehung gesetzt zu Parametern der Plaque-Instabilität, klinisch definiert durch kürzliche (< 60 Tage zurückliegende) ischämische Ereignisse (n=19) und histopathologisch definiert über den Nachweis einer Plaque-Ruptur (n=14). Außerdem wurde eine morphometrische Analyse der einzelnen Plaque-Komponenten durchgeführt und deren Ergebnisse zu den zellulären und klinischen Parametern in Beziehung gesetzt. Die Morphometrie ergab keine signifikanten Unterschiede zwischen symptomatischen vs. asymptomatischen und rupturierten vs. unrupturierten Plaques was die Größe der fibrotischen Deckplatte, die durchschnittliche Dicke (Kern-Lumen-Distanz) und die dünnsten bzw. dicksten Stellen der Deckplatte anbelangt. Anzahl und Konzentration apoptotischer glatter Muskelzellen war deutlich (p<0,001) erhöht in symptomatischen, klinisch instabilen, Karotisplaques. Allerdings waren die Apoptose-Raten in Präparaten, die eine Plaque-Ruptur aufwiesen, nicht signifikant erhöht. Darüber hinaus fand sich kein Hinweis darauf, dass erhöhte Apoptose-Raten zu einem quantifizierbaren Verlust glatter Gefäßmuskelzellen in der fibrotischen Deckplatte führen. Auf dem Boden dieser Ergebnisse kann gefolgert werden, dass erhöhten Apoptose-Raten glatter Gefäßmuskelzellen in der humanen Atherosklerose offenbar eine tragende Bedeutung bei der Entwicklung thrombembolischer Ereignisse zukommt. Allerdings wird die Annahme, dass erhöhte Apoptose-Raten über einen Verlust an glatten Gefäßmuskelzellen Einfluss auf die morphometrischen Eigenschaften der fibrotischen Deckplatte atherosklerotischer Karotis-Läsionen nehmen und zu deren Ausdünnung führen durch die vorliegende Untersuchung nicht gestützt. Vielmehr scheint es plausibel, dass die Apoptose glatter Muskelzellen im Rahmen inflammatorischer Prozesse Einfluss auf die Komposition der Karotisplaque nimmt und so über eine Desintegration der zellulären und bindegewebigen Bestandteile zu reduzierter mechanischer Widerstandskraft und Rupturneigung führt.
Sphingosine 1-phosphate (S1P), derived from membrane sphingolipids, is a pleiotropic bioactive lipid mediator capable of evoking complex immune phenomena. Studies have highlighted its importance regarding intracellular signaling cascades as well as membrane-bound S1P receptor (S1PR) engagement in various clinical conditions. In neurological disorders, the S1P–S1PR axis is acknowledged in neurodegenerative, neuroinflammatory, and cerebrovascular disorders. Modulators of S1P signaling have enabled an immense insight into fundamental pathological pathways, which were pivotal in identifying and improving the treatment of human diseases. However, its intricate molecular signaling pathways initiated upon receptor ligation are still poorly elucidated. In this review, the authors highlight the current evidence for S1P signaling in neurodegenerative and neuroinflammatory disorders as well as stroke and present an array of drugs targeting the S1P signaling pathway, which are being tested in clinical trials. Further insights on how the S1P–S1PR axis orchestrates disease initiation, progression, and recovery may hold a remarkable potential regarding therapeutic options in these neurological disorders.
The efficacy of statin-treatment in aneurysmal subarachnoid hemorrhage (SAH) remains controversial. We aimed to investigate the effects of statin-treatment in non-aneurysmal (na)SAH in accordance with animal research data illustrating the pathophysiology of naSAH. We systematically searched PubMed using PRISMA-guidelines and selected experimental studies assessing the statin-effect on SAH. Detecting the accordance of the applied experimental models with the pathophysiology of naSAH, we analyzed our institutional database of naSAH patients between 1999 and 2018, regarding the effect of statin treatment in these patients and creating a translational concept. Patient characteristics such as statin-treatment (simvastatin 40 mg/d), the occurrence of cerebral vasospasm (CVS), delayed infarction (DI), delayed cerebral ischemia (DCI), and clinical outcome were recorded. In our systematic review of experimental studies, we found 13 studies among 18 titles using blood-injection-animal-models to assess the statin-effect in accordance with the pathophysiology of naSAH. All selected studies differ on study-setting concerning drug-administration, evaluation methods, and neurological tests. Patients from the Back to Bedside project, including 293 naSAH-patients and 51 patients with simvastatin-treatment, were recruited for this analysis. Patients under treatment were affected by a significantly lower risk of CVS (p < 0.01; OR 3.7), DI (p < 0.05; OR 2.6), and DCI (p < 0.05; OR 3). Furthermore, there was a significant association between simvastatin-treatment and favorable-outcome (p < 0.05; OR 3). However, dividing patients with statin-treatment in pre-SAH (n = 31) and post-SAH (n = 20) treatment groups, we only detected a tenuously significant higher chance for a favorable outcome (p < 0.05; OR 0.05) in the small group of 20 patients with statin post-SAH treatment. Using a multivariate-analysis, we detected female gender (55%; p < 0.001; OR 4.9), Hunt&Hess ≤III at admission (p < 0.002; OR 4), no anticoagulant-therapy (p < 0.0001; OR 0.16), and statin-treatment (p < 0.0001; OR 24.2) as the main factors improving the clinical outcome. In conclusion, we detected a significantly lower risk for CVS, DCI, and DI in naSAH patients under statin treatment. Additionally, a significant association between statin treatment and favorable outcome 6 months after naSAH onset could be confirmed. Nevertheless, unified animal experiments should be considered to create the basis for developing new therapeutic schemes.
Introduction: Acute stroke care delivered by interdisciplinary teams is time-sensitive. Simulation-based team training is a promising tool to improve team performance in medical operations. It has the potential to improve process times, team communication, patient safety, and staff satisfaction. We aim to assess whether a multi-level approach consisting of a stringent workflow revision based on peer-to-peer review and 2–3 one-day in situ simulation trainings can improve acute stroke care processing times in high volume neurocenters within a 6 months period.
Methods and Analysis: The trial is being carried out in a pre-test-post-test design at 7 tertiary care university hospital neurocenters in Germany. The intervention is directed at the interdisciplinary multiprofessional stroke teams. Before and after the intervention, process times of all direct-to-center stroke patients receiving IV thrombolysis (IVT) and/or endovascular therapy (EVT) will be recorded. The primary outcome measure will be the “door-to-needle” time of all consecutive stroke patients directly admitted to the neurocenters who receive IVT. Secondary outcome measures will be intervention-related process times of the fraction of patients undergoing EVT and effects on team communication, perceived patient safety, and staff satisfaction via a staff questionnaire.
Interventions: We are applying a multi-level intervention in cooperation with three “STREAM multipliers” from each center. First step is a central meeting of the multipliers at the sponsor's institution with the purposes of algorithm review in a peer-to-peer process that is recorded in a protocol and an introduction to the principles of simulation training and debriefing as well as crew resource management and team communication. Thereafter, the multipliers cooperate with the stroke team trainers from the sponsor's institution to plan and execute 2–3 one-day simulation courses in situ in the emergency department and CT room of the trial centers whereupon they receive teaching materials to perpetuate the trainings.
Clinical Trial Registration: STREAM is a registered trial at https://clinicaltrials.gov/ct2/show/NCT03228251.
Background: The objective of the STREAM Trial was to evaluate the effect of simulation training on process times in acute stroke care.
Methods: The multicenter prospective interventional STREAM Trial was conducted between 10/2017 and 04/2019 at seven tertiary care neurocenters in Germany with a pre- and post-interventional observation phase. We recorded patient characteristics, acute stroke care process times, stroke team composition and simulation experience for consecutive direct-to-center patients receiving intravenous thrombolysis (IVT) and/or endovascular therapy (EVT). The intervention consisted of a composite intervention centered around stroke-specific in situ simulation training. Primary outcome measure was the ‘door-to-needle’ time (DTN) for IVT. Secondary outcome measures included process times of EVT and measures taken to streamline the pre-existing treatment algorithm.
Results: The effect of the STREAM intervention on the process times of all acute stroke operations was neutral. However, secondary analyses showed a DTN reduction of 5 min from 38 min pre-intervention (interquartile range [IQR] 25–43 min) to 33 min (IQR 23–39 min, p = 0.03) post-intervention achieved by simulation-experienced stroke teams. Concerning EVT, we found significantly shorter door-to-groin times in patients who were treated by teams with simulation experience as compared to simulation-naive teams in the post-interventional phase (−21 min, simulation-naive: 95 min, IQR 69–111 vs. simulation-experienced: 74 min, IQR 51–92, p = 0.04).
Conclusion: An intervention combining workflow refinement and simulation-based stroke team training has the potential to improve process times in acute stroke care.
Background: Treatment of acute stroke is highly time-dependent and performed by a multiprofessional, interdisciplinary team. Interface problems are expectable and issues relevant to patient safety are omnipresent. The Safety Attitudes Questionnaire (SAQ) is a validated and widely used instrument to measure patient safety climate. The objective of this study was to evaluate the SAQ for the first time in the context of acute stroke care. Methods: A survey was carried out during the STREAM trial (NCT 032282) at seven university hospitals in Germany from October 2017 to October 2018. The anonymous survey included 33 questions (5-point Likert scale, 1 = disagree to 5 = agree) and addressed the entire multiprofessional stroke team. Statistical analyses were used to examine psychometric properties as well as descriptive findings. Results: 164 questionnaires were completed yielding a response rate of 66.4%. 67.7% of respondents were physicians and 25.0% were nurses. Confirmatory Factor Analysis revealed that the original 6-factor structure fits the data adequately. The SAQ for acute stroke care showed strong internal consistency (α = 0.88). Exploratory analysis revealed differences in scores on the SAQ dimensions when comparing physicians to nurses and when comparing physicians according to their duration of professional experience. Conclusion: The SAQ is a helpful and well-applicable tool to measure patient safety in acute stroke care. In comparison to other high-risk fields in medicine, patient safety climate in acute stroke care seems to be on a similar level with the potential for further improvements. Trial registration: www.ClinicalTrials.gov Identifier: NCT032282.
Background and purpose: Impaired kidney function is associated with an increased risk of vascular events in acute stroke patients, when assessed by single measurements of estimated glomerular filtration rate (eGFR). It is unknown whether repeated measurements provide additional information for risk prediction.
Methods: The MonDAFIS (Systematic Monitoring for Detection of Atrial Fibrillation in Patients with Acute Ischemic Stroke) study randomly assigned 3465 acute ischemic stroke patients to either standard procedures or an additive Holter electrocardiogram. Baseline eGFR (CKD-EPI formula) were dichotomized into values of < versus ≥60 ml/min/1.73 m2. eGFR dynamics were classified based on two in-hospital values as “stable normal” (≥60 ml/min/1.73 m2), “increasing” (by at least 15% from baseline, second value ≥ 60 ml/min/1.73 m2), “decreasing” (by at least 15% from baseline of ≥60 ml/min/1.73 m2), and “stable decreased” (<60 ml/min/1.73 m2). The composite endpoint (stroke, major bleeding, myocardial infarction, all-cause death) was assessed after 24 months. We estimated hazard ratios in confounder-adjusted models.
Results: Estimated glomerular filtration rate at baseline was available in 2947 and a second value in 1623 patients. After adjusting for age, stroke severity, cardiovascular risk factors, and randomization, eGFR < 60 ml/min/1.73 m2 at baseline (hazard ratio [HR] = 2.2, 95% confidence interval [CI] = 1.40–3.54) as well as decreasing (HR = 1.79, 95% CI = 1.07–2.99) and stable decreased eGFR (HR = 1.64, 95% CI = 1.20–2.24) were independently associated with the composite endpoint. In addition, eGFR < 60 ml/min/1.732 at baseline (HR = 3.02, 95% CI = 1.51–6.10) and decreasing eGFR were associated with all-cause death (HR = 3.12, 95% CI = 1.63–5.98).
Conclusions: In addition to patients with low eGFR levels at baseline, also those with decreasing eGFR have increased risk for vascular events and death; hence, repeated estimates of eGFR might add relevant information to risk prediction.
Objectives: To assess tolerability and efficacy of lacosamide in adults with cerebrovascular epilepsy etiology (CVEE).
Materials and methods: Exploratory post hoc analyses of a double‐blind, initial monotherapy trial of lacosamide vs carbamazepine‐controlled release (carbamazepine‐CR) (SP0993; NCT01243177); a double‐blind conversion to lacosamide monotherapy trial (SP0902; NCT00520741); and an observational study of adjunctive lacosamide added to one antiepileptic drug (SP0973 VITOBA; NCT01098162). Patients with CVEE were identified based on epilepsy etiology recorded at baseline.
Results: In the initial monotherapy trial, 61 patients had CVEE (lacosamide: 27; carbamazepine‐CR: 34). 20 (74.1%) patients on lacosamide (27 [79.4%] on carbamazepine‐CR) reported treatment‐emergent adverse events (TEAEs), most commonly (≥10%) headache, dizziness, and fatigue (carbamazepine‐CR: headache, dizziness). A numerically higher proportion of patients on lacosamide than carbamazepine‐CR completed 6 months (22 [81.5%]; 20 [58.8%]) and 12 months (18 [66.7%]; 17 [50.0%]) treatment without seizure at last evaluated dose. In the conversion to monotherapy trial, 26/30 (86.7%) patients with CVEE reported TEAEs, most commonly (≥4 patients) dizziness, convulsion, fatigue, headache, somnolence, and cognitive disorder. During lacosamide monotherapy, 17 (56.7%) patients were 50% responders and six (20.0%) were seizure‐free. In the observational study, 36/83 (43.4%) patients with CVEE reported TEAEs, most commonly (≥5%) fatigue and dizziness. Effectiveness was assessed for 75 patients. During the last 3 months, 60 (80%) were 50% responders and 42 (56.0%) were seizure‐free.
Conclusions: These exploratory post hoc analyses suggested lacosamide was generally well tolerated and effective in patients with CVEE, with data from the initial monotherapy trial suggesting numerically better efficacy than carbamazepine‐CR.
With increasing distribution of endovascular stroke therapies, transient middle cerebral artery occlusion (tMCAO) in mice now more than ever depicts a relevant patient population with recanalized M1 occlusion. In this case, the desired therapeutic effect of blood flow restauration is accompanied by breakdown of the blood-brain barrier (BBB) and secondary reperfusion injury. The aim of this study was to elucidate short and intermediate-term transcriptional patterns and the involved pathways covering the different cellular players at the neurovascular unit after transient large vessel occlusion. To achieve this, male C57Bl/6J mice were treated according to an intensive post-stroke care protocol after 60 min occlusion of the middle cerebral artery or sham surgery to allow a high survival rate. After 24 h or 7 days, RNA from microvessel fragments from the ipsilateral and the contralateral hemispheres was isolated and used for mRNA sequencing. Bioinformatic analyses allowed us to depict gene expression changes at two timepoints of neurovascular post-stroke injury and regeneration. We validated our dataset by quantitative real time PCR of BBB-associated targets with well-characterized post-stroke dynamics. Hence, this study provides a well-controlled transcriptome dataset of a translationally relevant mouse model 24 h and 7 days after stroke which might help to discover future therapeutic targets in cerebral ischemia/reperfusion injury.